$-0.04
(Market cap
$101 Mln
Revenue (TTM)
$87 Mln
P/E Ratio
--
P/B Ratio
2.7
Div. Yield
0 %
Stock Range
Today’s Range
52 Week Range
Liquidity
Fundamentals
-
Net Profit (TTM)
$0 Mln
-
ROE
-0.9 %
-
ROCE
-- %
-
Industry P/E
44.46
-
EV/EBITDA
-5.6
-
Debt to Equity
1
-
Book Value
$0.9
-
EPS
$-1.2
-
Face value
--
-
Shares outstanding
42,237,203
10 Years Aggregate
CFO
$-204.44 Mln
EBITDA
$-227.15 Mln
Net Profit
$-252.71 Mln
Performance
|
Company
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|---|---|---|---|---|---|---|---|
|
Pulmonx Corp (LUNG)
| 7.7 | 95.1 | 54.5 | 28.0 | -39.6 | -43.2 | -- |
|
BSE Sensex*
| -9.3 | -1.4 | 2.7 | -3.7 | 5.7 | 6.2 | 10.5 |
|
S&P Small-Cap 600#
| -5.8 | -5.3 | -13.7 | -6.3 | 5.3 | 3.0 | 5.5 |
|
Company
|
2025
|
2024
|
2023
|
2022
|
2021
|
|---|---|---|---|---|---|
|
Pulmonx Corp (LUNG)
| -67.5 | -46.5 | 51.2 | -73.7 | -53.5 |
|
S&P Small-Cap 600
| 4.0 | 7.0 | 13.9 | -17.4 | 25.3 |
|
BSE Sensex
| 9.1 | 8.1 | 18.7 | 4.4 | 22.0 |
Essential Checks
View DetailsIs there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
Financials
View DetailsKey Ratios
View Details
5Y Avg -- 3Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Peers
View DetailsCompany |
Price ($) | Market Cap ($ Mln) | Revenue (TTM) | Net Profit (TTM) | OPM (%) | ROE (%) | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
|
Pulmonx Corp (LUNG)
|
2.4 | 100.5 | 87.4 | -48.1 | -55.1 | -103.1 | -- | 2.7 |
| 61.5 | 8,018.1 | 616.9 | -75.1 | 1.7 | -9.3 | -- | 10.2 | |
| 14.6 | 9,638.1 | 6,561.1 | -578.0 | -4.5 | -10.3 | -- | 1.7 | |
| 365.1 | 9,761.6 | 2,589.3 | 222.4 | -6.0 | 3 | 44.5 | 1.3 | |
| 57.1 | 8,696.7 | 3,499.6 | -71.2 | 0.5 | -3.2 | -- | 3.8 | |
| 179.9 | 10,905.5 | 612.8 | -188.1 | -30.6 | -28.1 | -- | 16.4 | |
| 100.8 | 6,577.5 | 1,556.3 | 275.3 | 24.6 | 22.9 | 24.1 | 5.0 | |
| 90.5 | 5,403.2 | 1,579.2 | 145.6 | 14.3 | 8.9 | 37.2 | 3.2 | |
| 321.7 | 12,752.7 | 1,504.9 | 160.6 | 13.6 | 10.9 | 79.4 | 8.4 | |
| 176.3 | 9,947.9 | 785.1 | 41.5 | 9.9 | 2 | 251.8 | 4.9 |
Shareholding Pattern
View DetailsAbout Pulmonx Corp (LUNG)
Pulmonx Corporation, a commercial-stage medical technology company that provides a minimally invasive treatment for patients with severe emphysema, a form of chronic obstructive pulmonary disease. It offers Zephyr Endobronchial Valve; and Chartis... Pulmonary Assessment System, a balloon catheter and console system with flow and pressure sensors that are used to assess the presence of collateral ventilation. The company also offers LungTraX Platform, a cloud-based quantitative computed tomography analysis service that provides physicians with multiple products, such as LungTraX Connect to improve workup efficiency; LungTraX Detect to enable patient identification; and StratX Lung report that is designed for solution that includes information on emphysema destruction, fissure completeness, and lobar volume to help identify target lobes for treatment with Zephyr Valves. It serves emphysema patients in the United States, Europe, the Middle East, Africa, the Asia Pacific, and internationally. The company was formerly known as Pulmonx and changed its name to Pulmonx Corporation in December 2013. Pulmonx Corporation was incorporated in 1995 and is headquartered in Redwood City, California. Read more
-
General Counsel & Secretary
Mr. David A. Lehman J.D.
-
General Counsel & Secretary
Mr. David A. Lehman
-
Headquarters
Redwood City, CA
-
Website
Value Research Ratings
Our rating system has guided millions of investors in the past 20 years.
FAQs for Pulmonx Corp (LUNG)
What is the current share price of Pulmonx Corp (LUNG) Today?
The share price of Pulmonx Corp (LUNG) is $2.38 (NASDAQ) as of 28-Aug-2026 16:00 EDT. Pulmonx Corp (LUNG) has given a return of -39.58% in the last 3 years.
What is the current PB & PE ratio of Pulmonx Corp (LUNG)?
Since, TTM earnings of Pulmonx Corp (LUNG) is negative, P/E ratio is not available.
The P/B ratio of Pulmonx Corp (LUNG) is 2.66 times as on 28-Aug-2026, a 30 discount to its peers’ median range of 3.79 times.
PE & PB ratio at the end of financial year.
| Year | P/E Ratio | P/B Ratio |
|---|---|---|
2025 |
-1.69 |
1.69 |
2024 |
-4.71 |
3.09 |
2023 |
-8.04 |
4.14 |
2022 |
-5.35 |
2.05 |
2021 |
-24.15 |
6.08 |
What is the 52 Week High and Low of Pulmonx Corp (LUNG)?
The 52-week high and low of Pulmonx Corp (LUNG) are Rs 2.89 and Rs 1.13 as of 31-Aug-2026.
What is the market cap of Pulmonx Corp (LUNG)?
Pulmonx Corp (LUNG) has a market capitalisation of $ 101 Mln as on 28-Aug-2026. As per SEBI classification, it is a Small Cap company.
Should I invest in Pulmonx Corp (LUNG)?
Before investing in Pulmonx Corp (LUNG), assess your goals, risk tolerance, and if the company aligns with your long-term plan. Carefully review its business model, financials, and valuation. Avoid making decisions based on tips or short-term trends.
New Process Alert 
Seems like you've uploaded a wrong QR code. Please upload the QR code downloaded from MF Central platform.